Repositioning Candidate Details
| Candidate ID: | R0892 |
| Source ID: | DB05888 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | MEM 1414 |
| Synonyms: | -- |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | MEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. This drug candidate has completed Phase 1 clinical trials. MEM 1414 works by blocking phosphodiesterase, an enzyme that breaks down an important brain chemical, cyclic AMP. It appears to work in the area of the brain where new memories are formed. |
| CAS Number: | -- |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in alzheimer's disease, depression, memory loss, and neurologic disorders. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | MEM 1414 is PDE4 inhibitor which is designed to selectively raise levels of cyclic adenosine monophosphate, or cAMP, by inhibiting the activity of PDE4, the enzyme which breaks down cAMP, and therefore they may be beneficial in restoring memory function. PDE4 inhibitors may also have potential therapeutic value in multiple other indications. |
| Targets: | CAMP phosphodiesterase |
| Inclusion Criteria: | Indication associated |
